SAR3419 is in clinical development for the treatment of non-Hodgkin's lymphoma, the predominant liquid tumor in the US today.

We licensed SAR3419 to sanofi-aventis from our preclinical pipeline as part of a broader collaboration. The compound consists of a CD19-binding antibody (created and humanized by ImmunoGen) with our DM4 payload attached using one of our engineered linkers.

Sanofi-aventis initiated two Phase I trials with SAR3419 - one assessing it when dosed every three weeks and one assessing it when dosed weekly. Impressive results have been seen, particularly in the weekly dosing study, and sanofi-aventis has made the "go" decision to advance SAR3419 into Phase II after obtaining some additional information in Phase I. Phase II testing is expected to start in 2H2011.